REGN – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$681.58Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $74,898,825,216.00
EPSttm : 40.42
Regeneron Pharmaceuticals, Inc.
$681.58
1.68%$11.65Float Short %
1.98
Margin Of Safety %
59
Put/Call OI Ratio
0.83
EPS Next Q Diff
-1.9
EPS Last/This Y
8.02
EPS This/Next Y
0.39
Price
682.22
Target Price
1030.86
Analyst Recom
1.83
Performance Q
-32.38
Relative Volume
1.29
Beta
0.09
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | REGN | 708.24 | 0.84 | 1.66 | 42904 |
| 2024-12-20 | REGN | 702.6 | 0.83 | 2.40 | 43497 |
| 2024-12-23 | REGN | 714.98 | 0.93 | 4.49 | 39964 |
| 2024-12-24 | REGN | 714.47 | 0.92 | 0.57 | 40281 |
| 2024-12-26 | REGN | 716.41 | 0.91 | 10.98 | 40297 |
| 2024-12-27 | REGN | 712.99 | 0.91 | 4.51 | 40415 |
| 2024-12-30 | REGN | 702 | 0.94 | 1.20 | 40005 |
| 2024-12-31 | REGN | 712.63 | 0.90 | 0.71 | 41268 |
| 2025-01-02 | REGN | 715.96 | 0.90 | 3.68 | 41717 |
| 2025-01-03 | REGN | 718.2 | 0.90 | 1.27 | 42172 |
| 2025-01-06 | REGN | 716.46 | 0.89 | 0.72 | 42109 |
| 2025-01-07 | REGN | 730.53 | 0.88 | 0.91 | 43031 |
| 2025-01-08 | REGN | 733.86 | 0.87 | 2.05 | 44767 |
| 2025-01-09 | REGN | 733.59 | 0.87 | 1.67 | 44767 |
| 2025-01-10 | REGN | 697 | 0.88 | 1.46 | 45489 |
| 2025-01-13 | REGN | 716.81 | 0.89 | 1.13 | 45834 |
| 2025-01-14 | REGN | 690.79 | 0.88 | 2.28 | 47881 |
| 2025-01-15 | REGN | 703.71 | 0.86 | 1.67 | 47912 |
| 2025-01-16 | REGN | 692.86 | 0.85 | 10.39 | 48336 |
| 2025-01-17 | REGN | 681.49 | 0.83 | 0.79 | 48228 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | REGN | 707.85 | -4.9 | -0.3 | 45.05 |
| 2024-12-20 | REGN | 702.06 | -4.9 | 3.8 | 45.05 |
| 2024-12-23 | REGN | 715.13 | -5.4 | 158.6 | 45.07 |
| 2024-12-24 | REGN | 714.47 | -5.4 | 90.0 | 45.07 |
| 2024-12-26 | REGN | 716.68 | -5.4 | 112.6 | 45.07 |
| 2024-12-27 | REGN | 712.62 | -5.4 | 63.3 | 45.07 |
| 2024-12-30 | REGN | 702.36 | -5.4 | 15.7 | 45.07 |
| 2024-12-31 | REGN | 712.50 | -5.4 | 174.9 | 45.07 |
| 2025-01-02 | REGN | 715.12 | -5.4 | 117.3 | 45.07 |
| 2025-01-03 | REGN | 717.74 | -5.4 | 115.3 | 45.07 |
| 2025-01-06 | REGN | 716.20 | -5.4 | 79.9 | 45.07 |
| 2025-01-07 | REGN | 730.54 | -5.4 | 207.5 | 45.07 |
| 2025-01-08 | REGN | 733.59 | -5.4 | 120.5 | 45.07 |
| 2025-01-09 | REGN | 733.59 | -5.4 | 95.2 | 45.07 |
| 2025-01-10 | REGN | 697.11 | -5.4 | -184.4 | 45.07 |
| 2025-01-13 | REGN | 717.37 | -5.4 | 261.3 | 45.07 |
| 2025-01-14 | REGN | 690.58 | -5.4 | -111.7 | 45.07 |
| 2025-01-15 | REGN | 703.43 | -5.4 | 198.0 | 45.07 |
| 2025-01-16 | REGN | 693.05 | -5.4 | 11.9 | 45.07 |
| 2025-01-17 | REGN | 682.22 | -5.2 | 5.4 | 45.07 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | REGN | -0.96 | -1.13 | 1.70 |
| 2024-12-20 | REGN | -0.96 | -1.13 | 1.70 |
| 2024-12-23 | REGN | -0.97 | -1.13 | 1.70 |
| 2024-12-24 | REGN | -0.97 | -1.13 | 1.70 |
| 2024-12-26 | REGN | -0.94 | -1.13 | 1.77 |
| 2024-12-27 | REGN | -0.94 | -1.13 | 1.77 |
| 2024-12-30 | REGN | -0.94 | -1.14 | 1.77 |
| 2024-12-31 | REGN | -0.94 | -1.14 | 1.77 |
| 2025-01-02 | REGN | -0.93 | -1.14 | 1.77 |
| 2025-01-03 | REGN | -0.91 | -1.14 | 1.77 |
| 2025-01-06 | REGN | -0.91 | -1.13 | 1.77 |
| 2025-01-07 | REGN | -0.91 | -1.13 | 1.77 |
| 2025-01-08 | REGN | -0.91 | -1.13 | 1.77 |
| 2025-01-09 | REGN | -0.91 | -1.13 | 1.77 |
| 2025-01-10 | REGN | -0.91 | -1.13 | 1.77 |
| 2025-01-13 | REGN | -0.86 | -1.10 | 1.98 |
| 2025-01-14 | REGN | -0.86 | -1.10 | 1.98 |
| 2025-01-15 | REGN | -0.86 | -1.10 | 1.98 |
| 2025-01-16 | REGN | -0.86 | -1.10 | 1.98 |
| 2025-01-17 | REGN | -0.86 | -1.10 | 1.98 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
12.46
Avg. EPS Est. Current Quarter
11.22
Avg. EPS Est. Next Quarter
10.56
Insider Transactions
-0.86
Institutional Transactions
-1.1
Beta
0.09
Average Sales Estimate Current Quarter
3763
Average Sales Estimate Next Quarter
3542
Fair Value
1085.65
Quality Score
99
Growth Score
75
Sentiment Score
43
Actual DrawDown %
43.7
Max Drawdown 5-Year %
-42.5
Target Price
1030.86
P/E
16.87
Forward P/E
15.22
PEG
2.81
P/S
5.41
P/B
2.56
P/Free Cash Flow
21.77
EPS
40.41
Average EPS Est. Cur. Y
45.07
EPS Next Y. (Est.)
45.46
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
33.61
Relative Volume
1.29
Return on Equity vs Sector %
-3.2
Return on Equity vs Industry %
9.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.16
EBIT Estimation
5.4
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 14165
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGN – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGN – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGN – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGN – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading